Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ARO-PNPLA3 / Arrowhead
NCT05039710: A Study of JNJ-75220795 in Japanese Participants	Terminated	1	9	Japan	JNJ-75220795, Placebo	Janssen Pharmaceutical K.K.	Fatty Liver	02/23	02/23
NCT04844450: A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795	Completed	1	55	US	JNJ-75220795, Placebo	Janssen Research & Development, LLC	Fatty Liver Disease	03/23	03/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ARO-PNPLA3 / Arrowhead
NCT05039710: A Study of JNJ-75220795 in Japanese Participants	Terminated	1	9	Japan	JNJ-75220795, Placebo	Janssen Pharmaceutical K.K.	Fatty Liver	02/23	02/23
NCT04844450: A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795	Completed	1	55	US	JNJ-75220795, Placebo	Janssen Research & Development, LLC	Fatty Liver Disease	03/23	03/23